Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
RPRobert P. GiuglianoTRTerje R. PedersenJPJeong-Gun ParkGMGaetano Maria De FerrariZGZbigniew Gaciong
Thrombolysis in Myocardial Infarction Study Group · Brigham and Women's Hospital · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
672
total citations
- FWCI
- 78.29
- Percentile
- 100%
- References
- 33
Citations per year
Authors
19- RPRobert P. GiuglianoCorresponding
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital
- TRTerje R. Pedersen
University of Oslo, Oslo University Hospital
- JPJeong-Gun Park
Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group
- GMGaetano Maria De Ferrari
University of Pavia, Policlinico San Matteo Fondazione
- ZGZbigniew Gaciong
Medical University of Warsaw
Topics & keywords
Topics
Keywords
- Evolocumab
- Medicine
- PCSK9
- Clinical endpoint
- Internal medicine
- Myocardial infarction
- Unstable angina
- Cholesterol
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.